Andrew Jenho Yee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrew Jenho Yee has a total of 427 co-authors. Here are the top co-authors by number of shared publications:
- Paul Gerard Richardson
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
48 shared publications - Jacob P. Laubach
Harvard Medical School, Boston, USA
45 shared publications Noopur S. Raje
Mass General Brigham Cancer Institute, Boston, USA
45 shared publicationsKenneth C. Anderson
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
43 shared publicationsHannah Stuart
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
40 shared publicationsJens G. Lohr
Dana-Farber Cancer Institute, Boston, MA
40 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 195
Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
- 2 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 195
Open AccessDenosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Long-term Outcomes of Modified-Intensity Lenalidomide, Bortezomib, and Dexamethasone (RVD-Lite) in Transplant-Ineligible Multiple Myeloma: Final Report of a Phase II Trial
Purpose: We report the long-term survival outcomes of a modified-intensity lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen as a first-line treatment for transplant-ineligible multiple myeloma. Patients and Methods: RVD-lite was evaluated in an investigator-initiated, multicenter phase II trial in patients with transplant-ineligible multiple myeloma. RVD-lite was administered over a 35-day cycle with lenalidomide 15 mg orally on days 1 to 21; bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, 15, and 22; and dexamethasone 20 mg orally on days 1, 2, 8, 9, 15, 16, 22, and 23 in patients ≤75 years of age and on days 1, 8, 15, and 22 in patients >75 years of age for 9 cycles of induction followed by 6 cycles of consolidation (lenalidomide + bortezomib). Lenalidomide maintenance was not mandated. Results: Fifty patients were enrolled. The median age was 73 years (range, 65–91), and 14% of patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2. At best response, the overall response rate (ORR) and ≥ very good partial response (VGPR) were 90% and 66%, respectively. After a median follow-up of 72 months, the median progression-free survival (PFS) was 42 months (5-year PFS: 40%), and the median overall survival (OS) was 76 months (5-year OS: 63%). An ECOG performance status of 2 was associated with inferior PFS and OS. Thirty-three (66%) patients received lenalidomide maintenance. Two (4%) patients discontinued treatment because of toxicity, and there was no treatment-related mortality. Conclusions: RVD-lite is a well-tolerated and highly effective regimen in transplant-ineligible multiple myeloma with prolonged PFS and OS. This study provides the framework for frailty-adapted triplet and quadruplet regimens in patients with multiple myeloma. This trial was registered at ClinicalTrials.gov (NCT01782963).
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Long-term Outcomes of Modified-Intensity Lenalidomide, Bortezomib, and Dexamethasone (RVD-Lite) in Transplant-Ineligible Multiple Myeloma: Final Report of a Phase II Trial
Purpose: We report the long-term survival outcomes of a modified-intensity lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen as a first-line treatment for transplant-ineligible multiple myeloma. Patients and Methods: RVD-lite was evaluated in an investigator-initiated, multicenter phase II trial in patients with transplant-ineligible multiple myeloma. RVD-lite was administered over a 35-day cycle with lenalidomide 15 mg orally on days 1 to 21; bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, 15, and 22; and dexamethasone 20 mg orally on days 1, 2, 8, 9, 15, 16, 22, and 23 in patients ≤75 years of age and on days 1, 8, 15, and 22 in patients >75 years of age for 9 cycles of induction followed by 6 cycles of consolidation (lenalidomide + bortezomib). Lenalidomide maintenance was not mandated. Results: Fifty patients were enrolled. The median age was 73 years (range, 65–91), and 14% of patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2. At best response, the overall response rate (ORR) and ≥ very good partial response (VGPR) were 90% and 66%, respectively. After a median follow-up of 72 months, the median progression-free survival (PFS) was 42 months (5-year PFS: 40%), and the median overall survival (OS) was 76 months (5-year OS: 63%). An ECOG performance status of 2 was associated with inferior PFS and OS. Thirty-three (66%) patients received lenalidomide maintenance. Two (4%) patients discontinued treatment because of toxicity, and there was no treatment-related mortality. Conclusions: RVD-lite is a well-tolerated and highly effective regimen in transplant-ineligible multiple myeloma with prolonged PFS and OS. This study provides the framework for frailty-adapted triplet and quadruplet regimens in patients with multiple myeloma. This trial was registered at ClinicalTrials.gov (NCT01782963).
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- Open Access
- 28 September 2026
- Published by Springer Nature in Blood Cancer Journal
Hypogammaglobulinemia, neutropenia, and lymphopenia, and risk for infection and mortality in patients following daratumumab for multiple myeloma
Daratumumab is an IgG kappa monoclonal antibody targeting CD38 approved for the treatment of multiple myeloma. While lymphopenia and neutropenia have been described, the broader immunologic impact, including hypogammaglobulinemia (IgG ≤600 mg/dL), remains undercharacterized. We performed a retrospective analysis of 614 adults receiving daratumumab for multiple myeloma; evaluating demographics, disease characteristics, hypogammaglobulinemia, lymphopenia, neutropenia, infections, immunoglobulin replacement (IVIG) use, and mortality. Mean IgG levels decreased from 568 mg/dL to 371 mg/dL following daratumumab, and hypogammaglobulinemia prevalence rose from 64.3% to 87.9%, with increasing severity. Lymphopenia and neutropenia prevalence and severity also increased. Hypogammaglobulinemia pre-daratumumab was associated with increased risk for infection (IRR 1.28, 95% CI 1.08–1.51), with severe hypogammaglobulinemia conferring the highest risk (IRR 1.85, 95% CI 1.45–2.35). Lower IgG levels were associated with infection risk. Baseline hypogammaglobulinemia, lymphopenia, and neutropenia were associated with increased mortality. When IVIG exposure was modeled as a time-varying variable, infection risk was significantly higher during periods off of IVIG compared with on IVIG (IRR 2.43, 95% CI 1.70–3.48). These findings support closer monitoring of IgG, ALC, and ANC beginning prior to daratumumab initiation and continued at regular intervals, with earlier consideration of immunoglobulin replacement in patients with hypogammaglobulinemia and infectious complications.
- 28 September 2026
- Published by Springer Nature in Blood Cancer Journal
Open AccessHypogammaglobulinemia, neutropenia, and lymphopenia, and risk for infection and mortality in patients following daratumumab for multiple myeloma
Daratumumab is an IgG kappa monoclonal antibody targeting CD38 approved for the treatment of multiple myeloma. While lymphopenia and neutropenia have been described, the broader immunologic impact, including hypogammaglobulinemia (IgG ≤600 mg/dL), remains undercharacterized. We performed a retrospective analysis of 614 adults receiving daratumumab for multiple myeloma; evaluating demographics, disease characteristics, hypogammaglobulinemia, lymphopenia, neutropenia, infections, immunoglobulin replacement (IVIG) use, and mortality. Mean IgG levels decreased from 568 mg/dL to 371 mg/dL following daratumumab, and hypogammaglobulinemia prevalence rose from 64.3% to 87.9%, with increasing severity. Lymphopenia and neutropenia prevalence and severity also increased. Hypogammaglobulinemia pre-daratumumab was associated with increased risk for infection (IRR 1.28, 95% CI 1.08–1.51), with severe hypogammaglobulinemia conferring the highest risk (IRR 1.85, 95% CI 1.45–2.35). Lower IgG levels were associated with infection risk. Baseline hypogammaglobulinemia, lymphopenia, and neutropenia were associated with increased mortality. When IVIG exposure was modeled as a time-varying variable, infection risk was significantly higher during periods off of IVIG compared with on IVIG (IRR 2.43, 95% CI 1.70–3.48). These findings support closer monitoring of IgG, ALC, and ANC beginning prior to daratumumab initiation and continued at regular intervals, with earlier consideration of immunoglobulin replacement in patients with hypogammaglobulinemia and infectious complications.
- 1 September 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (5)
Toward a Cure in Multiple Myeloma: Redefining Induction Therapy and the Role of Autologous Stem Cell Transplant
The therapeutic goal in multiple myeloma (MM) is changing from long-term disease control to a potential cure. While anti-CD38-containing quadruplets have improved outcomes, relapses continue to occur in many patients. In recent years, advancements in immunotherapy have fundamentally changed this paradigm. Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cells (CAR T-cells) have deepened responses and achieved sustained MRD negativity in an unprecedented way, raising the possibility of curing MM in a subset of patients. Recently, the International Myeloma Society (IMS) reached a consensus and discussed a framework to define cure. This review examines how novel immunotherapies are redefining frontline strategies in newly diagnosed MM (NDMM) and attempts to summarize how BsAbs, CAR T-cells, and cereblon E3 ligase modulators (CELMoDs) can be integrated into induction, consolidation, and maintenance phases. It also discusses the evolving role of autologous stem cell transplant (ASCT) in the immunotherapy era and MRD-guided treatment and discontinuation strategies. Together, this review attempts to provide a roadmap to fulfill the criteria for cure.
- 1 September 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (5)
Toward a Cure in Multiple Myeloma: Redefining Induction Therapy and the Role of Autologous Stem Cell Transplant
The therapeutic goal in multiple myeloma (MM) is changing from long-term disease control to a potential cure. While anti-CD38-containing quadruplets have improved outcomes, relapses continue to occur in many patients. In recent years, advancements in immunotherapy have fundamentally changed this paradigm. Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cells (CAR T-cells) have deepened responses and achieved sustained MRD negativity in an unprecedented way, raising the possibility of curing MM in a subset of patients. Recently, the International Myeloma Society (IMS) reached a consensus and discussed a framework to define cure. This review examines how novel immunotherapies are redefining frontline strategies in newly diagnosed MM (NDMM) and attempts to summarize how BsAbs, CAR T-cells, and cereblon E3 ligase modulators (CELMoDs) can be integrated into induction, consolidation, and maintenance phases. It also discusses the evolving role of autologous stem cell transplant (ASCT) in the immunotherapy era and MRD-guided treatment and discontinuation strategies. Together, this review attempts to provide a roadmap to fulfill the criteria for cure.
- Open Access
- 2 June 2026
- Published by Association for Computing Machinery (ACM) in ACM Transactions on Computing for Healthcare
Evaluating Physician-AI Interaction for Cancer Management: Paving the Path toward Precision Oncology
As machine learning (ML)-based decision support tools proliferate in clinical practice, understanding how clinicians integrate personalized ML predictions alongside randomized controlled trial (RCT) evidence is critical. We designed a web-based clinical decision support system (CDSS) presenting survival and adverse event data from a simulated RCT and ML model across 12 synthetic multiple myeloma scenarios. In a within-subjects study with 32 physicians, we evaluated how clinicians synthesize competing evidence sources to make treatment decisions. When ML and RCT outputs were concordant, physicians reported greater confidence than with RCT data alone. When results were discordant, most physicians shifted toward the ML-supported treatment, often before reviewing any information about model training or validation, suggesting a tendency toward automation bias rather than algorithm avoidance. Despite reporting higher perceived reliability after viewing model quality disclosures, physicians were largely unable to describe the validation procedures they had reviewed. Taken together, these findings reveal that clinicians may over-rely on ML recommendations even when equipped with tools designed to support critical appraisal. We discuss implications for CDSS design, clinician training, and the institutional safeguards needed before ML-based systems are deployed in high-stakes oncology settings.
- 2 June 2026
- Published by Association for Computing Machinery (ACM) in ACM Transactions on Computing for Healthcare
Open AccessEvaluating Physician-AI Interaction for Cancer Management: Paving the Path toward Precision Oncology
As machine learning (ML)-based decision support tools proliferate in clinical practice, understanding how clinicians integrate personalized ML predictions alongside randomized controlled trial (RCT) evidence is critical. We designed a web-based clinical decision support system (CDSS) presenting survival and adverse event data from a simulated RCT and ML model across 12 synthetic multiple myeloma scenarios. In a within-subjects study with 32 physicians, we evaluated how clinicians synthesize competing evidence sources to make treatment decisions. When ML and RCT outputs were concordant, physicians reported greater confidence than with RCT data alone. When results were discordant, most physicians shifted toward the ML-supported treatment, often before reviewing any information about model training or validation, suggesting a tendency toward automation bias rather than algorithm avoidance. Despite reporting higher perceived reliability after viewing model quality disclosures, physicians were largely unable to describe the validation procedures they had reviewed. Taken together, these findings reveal that clinicians may over-rely on ML recommendations even when equipped with tools designed to support critical appraisal. We discuss implications for CDSS design, clinician training, and the institutional safeguards needed before ML-based systems are deployed in high-stakes oncology settings.
- Top Cited Papers
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2215-2225
Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea
Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2215-2225
Top Cited PapersRuxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea
Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
- Open Access
- 28 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 64
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
- 28 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 64
Open AccessImmune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
- Open Access
- 22 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.
The new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (MM) was recently updated by the International Myeloma Society and International Myeloma Working Group. We performed a retrospective study to validate the revised HRMM criteria in relapsed and refractory MM patients treated with BCMA CAR-T. A total of 158 patients were included, of whom 75 (47%) met criteria for HRMM. The median follow-up was 24.8 months (95% CI 22.5–30.3). On multivariable analysis, patients with HRMM had significantly shorter PFS (HR 1.89, p = 0.003) and OS (HR 3.06, p < 0.001) compared to standard-risk MM (SRMM) following BCMA CAR-T. LDH > 210 U/L and EMD were also identified as independent adverse risk factors. Based on survival analyses, we constructed a reclassified staging system incorporating LDH and EMD into the CGS-HRMM criteria. Patients were divided into four discrete risk groups: low risk (SRMM with normal LDH and no EMD; n = 42, 26%), intermediate-low risk (HRMM with normal LDH and no EMD; n = 31, 20%), intermediate-high risk (SRMM with high LDH, EMD, or both; n = 41, 26%), and high risk (HRMM with high LDH, EMD, or both; n = 44, 28%). Patients with low, intermediate-low, intermediate-high, and high-risk disease had a median PFS of 35.0, 19.6, 10.4, and 6.6 months, respectively (p < 0.0001), and an estimated 24-month OS of 90%, 69%, 66%, and 26%, respectively (p < 0.0001). In summary, we validated the new CGS-HRMM criteria in relapsed and refractory MM patients treated with BCMA CAR-T. We also propose a reclassified staging system to further improve risk stratification in MM patients treated with BCMA CAR-T.
- 22 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessValidation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.
The new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (MM) was recently updated by the International Myeloma Society and International Myeloma Working Group. We performed a retrospective study to validate the revised HRMM criteria in relapsed and refractory MM patients treated with BCMA CAR-T. A total of 158 patients were included, of whom 75 (47%) met criteria for HRMM. The median follow-up was 24.8 months (95% CI 22.5–30.3). On multivariable analysis, patients with HRMM had significantly shorter PFS (HR 1.89, p = 0.003) and OS (HR 3.06, p < 0.001) compared to standard-risk MM (SRMM) following BCMA CAR-T. LDH > 210 U/L and EMD were also identified as independent adverse risk factors. Based on survival analyses, we constructed a reclassified staging system incorporating LDH and EMD into the CGS-HRMM criteria. Patients were divided into four discrete risk groups: low risk (SRMM with normal LDH and no EMD; n = 42, 26%), intermediate-low risk (HRMM with normal LDH and no EMD; n = 31, 20%), intermediate-high risk (SRMM with high LDH, EMD, or both; n = 41, 26%), and high risk (HRMM with high LDH, EMD, or both; n = 44, 28%). Patients with low, intermediate-low, intermediate-high, and high-risk disease had a median PFS of 35.0, 19.6, 10.4, and 6.6 months, respectively (p < 0.0001), and an estimated 24-month OS of 90%, 69%, 66%, and 26%, respectively (p < 0.0001). In summary, we validated the new CGS-HRMM criteria in relapsed and refractory MM patients treated with BCMA CAR-T. We also propose a reclassified staging system to further improve risk stratification in MM patients treated with BCMA CAR-T.